Table 1 Definition and quantification of input parameter
Parameter | Description | Value | Reference |
|---|---|---|---|
P t | MRSA prevalence of all inpatients | 3.075 % | [14] |
P r | MRSA prevalence of high-risk inpatients | 11.94 % | [14] |
P n. i. | MRSA prevalence of patients without indication for a targeted screening | 2.09 % | Calculation based on in-house data (UMG)a |
RT no iso | Rate of MRSA transmission not in isolation per day | 0.0443 | |
RT iso | Rate of MRSA transmission in isolation per day | 0.0033 | |
Sen PoC | Sensitivity of PoC method | 95 % | In-house data (mölnlycke hc) |
Sen PCR | Sensitivity of PCR method | 91.09 % | [14] |
Sen cul | Sensitivity of culture method | 88.73 % | [14] |
SP PoC | Specificity of PoC method | 97.5 % | In-house data (mölnlycke hc) |
SP PCR | Specificity of PCR method | 95.79 % | [14] |
SP cul | Specificity of culture method | 93.23 % | [14] |
C pre iso | Average costs for pre-emptive isolation per day | 62.77 € | [14] |
C MRSA | Average costs per MRSA case per day | 506.92 € | [14] |
∅ LOS MRSA | Average length of stay of MRSA patients in days | 24.88 | [14] |
T PoC | Turn-around time of PoC method in days | 0.01389 | [9] |
T PCR | Turn-around time of PCR method in days | 0.29 | In-house data (UMG) |
T cul | Turn-around time of culture method in days | 2.5 | In-house data (UMG) |
C PoC | Costs for a single PoC test | 30 € | [9] |
C PCR | Costs for a single PCR test | 20.50 € | [14] |
C cul pos | Costs for a single culture test with positive result | 24.10 € | [14] |
C cul neg | Costs for a single culture test with negative result | 6.40 € | [14] |
C f | Costs for follow-up screening | 6.40 € | Costs of a negative culture test are assumed |
C c | Costs for screening a contact patient | 6.40 € | Costs of a negative culture test are assumed |
Pat c | Number of contact patients | 2 | calculation based on in-house data (UMG) |
∅ LOS reg | Average length of stay of regular patients in days | 8 | [14] |
Pat t | Number of total inpatients per year | 35,322 | In-house data (UMG) |
Pat risk | Number of high-risk patients per year | 3,532 | In-house data (UMG) |
Pat n. i. | Number of patients without indication for a targeted screening per year | 31,790 | In-house data (UMG) |